Clinical trial · Observational
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)
NCT04150289CI-TRIAL-00067144RECOMMcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Farydak | Drug | Panobinostat | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response to treatment
- timeFrame
- 24 months
- description
- Looking for patient reproted response to treatment with panobinostat
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Willing and able to provide written informed consent * At least 18 years of age * Clinical diagnosis of multiple myeloma that meets published diagnostic criteria * Initiating panobinostat within 60 days of enrollment * ECOG performance status 0-1 * Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response * Willing and able to complete the PRO questionnaire Exclusion Criteria: * Diagnosed with any B-cell malignancy other than myeloma * Estimated life expectancy \<6 months * Currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)
References
Publications (0)
Data not yet available
No reference posted for this study.